

Is it TRUE?

A Public Health Program on Vitamin D and Disease Prevention Sponsored by GrassrootsHealth

Carole A Baggerly Director, GrassrootsHealth Cedric F. Garland, Dr. P.H. Professor, UCSD Department of Family & Preventive Medicine, Moores Cancer Center




Basis for Recommendations

40-60 ng/ml serum hydroxyvitamin D level (100-150 nmol/L)

2000 IU/day is safe

Vitamin D Status in Primates and Early Humans



Sources, include Cosman, Osteoporosis Int 2000; Fuleihan NEJM 1999; Scharla Osteoporosis Int 1998; Vieth AJCN 1999, 2000

Serum 25(OH)D, ng/ml	6	8	10	12	14	16	18	20	22	24	26	28	30	32	34	36	38	40	42	44	46	48	50	52	54	56	58	60	62	64	66	68
Studies of Individuals																	1										-					
Cancers, all combined																		35%														
Breast Cancer														30%		$\delta \theta_{\rm c}$	8	×	×	8	14	X	X	83%								
Ovarian Cancer																	12					179	6									
Colon Cancer														31	1%	3	8%	X	X	60%												
Non-Hodgkins Lymphoma										ivel			1	1	2%		5	18%			-		-									
Type 1 Diabetes										eLe					25%									6	6%				-			
Fractures, all combined										end						2	5%				50%											
Falls, women										efe	1	72%																				
Multiple Sclerosis										E							1		33%				4	6%	Х	54%	5					
Heart Attack (Men)		100								Seru		-				30%	10			1												
Natural Experiments																																
Kidney Cancer															23	%							49%									
Endometrial Cancer																						379	6									
	-																1															
Rickets 50	%							99%									1															


Disease Incidence Prevention by Serum 25(OH)D Level

**All percentages reference a common baseline of 25 ng/ml as shown on the chart. References:

All Cancers: Lappe JM, et al. Am J Clin Nutr. 2007;85:1586-91. Breast: Garland CF, Gorham ED, Mohr SB, Grant WB, Garland FC. Breast cancer risk according to serum 25-Hydroxyvitamin D: Meta-analysis of Dose-Response (abstract). American Association for Cancer Research Annual Meeting, 2008. Reference serum 25(OH) D was 5 ng/ml. Garland, CF, et al. Amer Assoc Cancer Research Annual Mtg, April 2008, Colon: Gorham ED, et al. Am J Prev Med. 2007;32:210-6. Diabetes: Hyppönen E, et al. Lancet 2001;358:1500-3. Endometrium: Mohr SB, et al. Prev Med. 2007;45:323-4. Falls: Broe KE, et al. J Am Geriatr Soc. 2007;55:234-9. Fractures: Bischoff-Ferrari HA, et al. JAMA. 2005;293:2257-64. Heart Attack: Giovannucci et al. Arch Intern Med/Vol 168 (No 11) June 9, 2008. Multiple Sclerosis: Munger KL, et al. JAMA. 2006;296:2832-8. Non-Hodgkin's Lymphoma: Purdue MP, et al. Cancer Causes Control. 2007;18:989-99. Ovary: Tworoger SS, et al. Cancer Epidemiol Biomarkers Prev. 2007;16:783-8. Renal: Mohr SB, et al. Int J Cancer. 2006;119:2705-9. Rickets: Arnaud SB, et al. Pediatrics. 1976 Feb;57(2):221-5.

Copyright GrassrootsHealth, 07/26/08 www.grassrootshealth.org

VITAMIN D INTAKE & TOXICITY



Hathcock JN et al. Am J Clin Nutr. 2007;85:6–18.

www.grassrootshealth.org



By following the recommendations, it is estimated that we could have an ANNUAL


67-70% reduction in incidence of Breast Cancer Type 1 Diabetes Multiple Sclerosis Colon Cancer Within only 5 years!



Controlled Trials with D


- <u>All Cancers</u>, Lappe, 35% reduction incidence (1179 women, 28 ng/ml to 38 ng/ml, 1100 IU/d + Ca, 4 yr)
- Falls, Bischoff, 49% reduction incidence
 (122 women, 800 IU/d + Ca, 12-20 ng/ml, 12 wks)
- <u>Neuromuscular Function</u>, Wicherts, 1.8 times better performance at >30 ng/ml vs 10 ng/ml
- <u>Blood Pressure</u>, Pfeifer, 13 % reduction at approximately 30 ng/ml vs 20 ng/ml
 (148 women, 800 IU/d + Ca, 8 wks)
- Influenza, Aloia, 77% reduction at 38 ng/ml vs 18 ng/ml (208 African American women, 2000 IU/d, 3 yr)

VITAMIN D & CANCER




Lappe et al. AJCN 2007


VITAMIN D & CANCER




VITAMIN D & CANCER




80% Breast Cancer Incidence Reduction




Source: Garland et al. (2007) based on data in Lowe et al. (2006)



Data from: Lowe LC, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41:1164-9.




Data from: Bertone-Johnson, E.R. et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 1991-7.




Source: Garland CF, et al. Vitamin D and prevention of breast cancer: Pooled analysis, J Steroid Biochem Mol Biol. 2007;103:708-11

Garland, et al. Meta-Analysis of Dose Response, 2008



Lowe LC, et al. Plasma 25-hydroxy vitamin D ... Eur J Cancer. 2005;41:1164-9.
 Bertone-Johnson, E.R. et al. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1991-7.


Abbas S, et al. Serum 25-hydroxyvitamin D and risk of breast...Carcinogenesis. 2008;29:93-9.
 Woolfe B. [Methods for combining 2x2 tables.] Ann Hum Genet 1955;19:251-5.



Source: Hypponen, Lancet Nov 2001

VITAMIN D & RISK OF FALLING


- 122 women
- Age: 63–99
- DB-RCT
 - > Ca 1,200 mg/d
 - Ca + 800 IU Vit D
- 12 week duration
- 25(OH)D 12 ng/mL at baseline



VIT D & NEUROMUSCULAR FUNCTION

- 1359 men & women; mean age 75.5
- Amsterdam longitud. aging study
- neuromuscular performance measured on a scale of 0 to 12 (higher is better)
- each step statistically significant


Performance Score




Wicherts et al. JBMR. 2005.

VIT D & BLOOD PRESSURE

- 148 women, aged
 74 ± 1
- DB-RCT
- baseline 25(OH)D < 20 ng/ml
- treated for 8 wks with: Ca 1200 mg/d or Ca + 800 IU vit D/d




30-50% Hypertension Burden Reduction



Source: Forman, Giovannucci 2007

VITAMIN D & INFLUENZA

- 208 African-American, postmenopausal women
- 3 yr DB-RCT
- placebo or vit D₃
 - 800 IU/d 2 yrs
 - > 2000 IU/d 3rd yr
- basal 25(OH)D: 18.8 ± 7.5
- P < 0.002



Disease Summary

- Disease List for very positive effects is extensive—breast cancer, type 1 diabetes, multiple sclerosis, colon cancer, heart disease, falls, fractures
- The 'some help' list includes aggressive prostate cancer, endometrial cancer, both lymphoma's, lung cancer

Disease Summary, cont.

To be researched, studied more

- » Brain development/cognition
- > Infectious Diseases
- Pain
- > Autism
- > Depression
- > Mental Illness



What's D*action?




A 5 year public health project to provide education and research to SOLVE the vitamin D deficiency epidemic

By measuring serum levels, health data and Tracking the health effects of getting serum Levels to 40-60 ng/ml (100-150 nmol/L)



Cedric F. Garland, Dr. P.H., Professor, University of California School of Family & Preventive Medicine is leading the research team with the data analysis.

51% Vitamin D Deficient



D*action study results



TAKE ACTION NOW! We know enough to reduce diseases today!

- 1. Measure your serum level (sign up for D*action and participate in the study) *www.joindaction.org*
- 2. Adjust serum level to 40-60 ng/ml (100-150 nmol/L)
- 3. Spread the word to everyone you know!